Clinical trial
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
NCT02431260
Study timeline
Study start (actual)2015-04-14Date precision: day
Registry last updated2019-06-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumors and Hematologic Malignancyunresolved
Interventions
Sponsors & collaborators
Incyte Corporationlead sponsor
Mapped research locations
ChicagoIllinois, United States2HoustonTexas, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1DenverColorado, United States1Ann ArborMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02431260 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.